[Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]

National Committee for Technology Incorporation (Conitec)
Record ID 32018001047
Portuguese
Original Title: Antimuscarínicos (oxibutinina, tolterodina, solifenacina e darifenacina) para o tratamento da disfunção de armazenamento em pacientes com bexiga neurogênica
Authors' objectives: What is the efficacy and safety of oxybutynin, tolterodine, solifenacin and darifenacin for storage dysfunction in adult patients with neurogenic bladder?
Authors' results and conclusions: The CONITEC’s members present at the 85th Ordinary Meeting, on February 4th, 2020, unanimously decided not to recommend the incorporation of antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) in the scope of SUS, for the treatment of storage dysfunction in patients with neurogenic bladder.
Authors' recommendations: Scientific evidence: For the question about the efficacy and safety of antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin), 868 references were retrieved through the search strategies, of which five randomized controlled trial (RCTs) were selected. The main efficacy outcomes assessed by these RCTs were: maximal bladder capacity, number of incontinence episodes per day, number of catheterizations per day, Incontinence Quality of Life (I-QoL), and Patient Perception of Bladder Condition (PPBC) score. In addition to the efficacy outcomes, adverse events were also assessed. One of the RCTs reported that intravesical oxybutynin provided a greater increase in cystometric volume than oral oxybutynin (mean increase [standard deviation - SD] of 116.6 [27.5] mL and 18.1 [27.5] mL, respectively, p=0.009). Another RCT reported that solifenacin 5 mg and 10 mg and oxybutynin 15 mg provided a significant increase in cystometric volume compared with placebo (mean increase [SD] of 77.8 [115.4] mL, 134.2 [124.7] mL and 134.2 [124.7] mL, respectively, p
Details
Project Status: Completed
URL for project: http://conitec.gov.br/images/Consultas/Relatorios/EN2020/20200915_Report508_Antimuscarinics_NeurogenicBladder.pdf
Year Published: 2020
URL for published report: http://conitec.gov.br/images/Relatorios/2020/Relatorio_Antimuscarinicos_Bexiga_Neurogenica_508_2020_FINAL.pdf
URL for additional information: http://conitec.gov.br/recomendation-reports
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Brazil
MeSH Terms
  • Urinary Bladder, Neurogenic
  • Drug Therapy
  • Muscarinic Antagonists
  • Urological Agents
Keywords
  • Antimuscarinics
  • oxybutynin
  • tolterodine
  • solifenacin
  • darifenacin
  • neurogenic bladder
  • storage dysfunction
Contact
Organisation Name: National Committee for Technology Incorporation (CONITEC)
Contact Address: Esplanada dos Ministérios, Bl. G, Ed. Sede, 8º andar, CEP: 70058-900
Contact Name: Clarice Moreira Portugal
Contact Email: clarice.portugal@saude.gov.br
Copyright: 2021 Conitec
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.